NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

NRx Pharmaceuticals NRXP has announced enhancements to its Expanded Access and Right to Try programs

  • The programs enable patients to receive Zyesami (aviptadil) upon a physician's prescription, with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who cannot participate in a clinical study.
  • This expansion comes as supplies of Zyesami have increased through the partnership between NRx and Nephron Pharmaceuticals. 
  • Related: NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights.
  • The expanded production will also support the ongoing ACTIV-3b trial conducted by the National Institutes of Health (NIH) in the US and Brazil.
  • Zyesami is a long-term stable form of vasoactive intestinal peptide, which was previously shown to be associated with a two-fold increased odds of survival at 60 days. 
  • The subgroup of patients treated with Zyesami after remdesivir and other approved therapies demonstrated a 2.8-fold increased odds of recovering from respiratory failure by day 28, which was sustained to day 60, together with a four-fold increased odds of surviving to day 60.
  • Zyesami is currently in Phase 3 trial being conducted by the National Institutes of Health (NIH).
  • Price Action: NRXP shares are 1.61% at $4.43 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!